AP502A - Multiple branch peptide constructions for use against HIV. - Google Patents

Multiple branch peptide constructions for use against HIV. Download PDF

Info

Publication number: AP502A
Authority: AP; ARIPO
Prior art keywords: peptides; hiv; peptide; amino acid; mbpc
Prior art date: 1993-09-13

Application number

APAP/P/1994/000680A

Other languages

English (en)

Other versions

AP9400680A0 (en

Inventor

Jean-Marc Sabatier

Abdelaziz Benjouad

Nouara Yahi

Emmanuel Fenouillet

Kamel Mabrouk

Jean-Claude Gluckman

Rietschoten Jurphaas Van

Herve Rochat

Original Assignee

Cellpep Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-13

Filing date

1994-09-13

Publication date

1996-06-07

1993-09-13 Priority claimed from GB939318901A external-priority patent/GB9318901D0/en

1994-09-13 Application filed by Cellpep Sa filed Critical Cellpep Sa

1994-10-31 Publication of AP9400680A0 publication Critical patent/AP9400680A0/xx

1996-06-07 Application granted granted Critical

1996-06-07 Publication of AP502A publication Critical patent/AP502A/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 122
238000010276 construction Methods 0.000 title claims abstract description 35
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 60
208000031886 HIV Infections Diseases 0.000 claims abstract description 41
239000011159 matrix material Substances 0.000 claims description 31
241000725303 Human immunodeficiency virus Species 0.000 claims description 26
238000000034 method Methods 0.000 claims description 26
125000000539 amino acid group Chemical group 0.000 claims description 25
210000002966 serum Anatomy 0.000 claims description 16
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 15
230000002401 inhibitory effect Effects 0.000 claims description 9
101710121417 Envelope glycoprotein Proteins 0.000 claims description 6
239000011347 resin Substances 0.000 claims description 6
229920005989 resin Polymers 0.000 claims description 6
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
230000002163 immunogen Effects 0.000 claims description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
125000006850 spacer group Chemical group 0.000 claims description 3
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 claims description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 2
230000008878 coupling Effects 0.000 claims description 2
238000010168 coupling process Methods 0.000 claims description 2
238000005859 coupling reaction Methods 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
229910000040 hydrogen fluoride Inorganic materials 0.000 claims description 2
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 2
239000007790 solid phase Substances 0.000 claims description 2
230000009897 systematic effect Effects 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 6
239000003814 drug Substances 0.000 claims 3
VJLLLMIZEJJZTE-VNQXHBPZSA-N HexCer(d18:1/16:0) Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O VJLLLMIZEJJZTE-VNQXHBPZSA-N 0.000 claims 2
238000003776 cleavage reaction Methods 0.000 claims 2
230000007017 scission Effects 0.000 claims 2
102100021696 Syncytin-1 Human genes 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
150000001413 amino acids Chemical class 0.000 abstract description 23
230000000694 effects Effects 0.000 abstract description 23
210000002540 macrophage Anatomy 0.000 abstract description 16
108020003175 receptors Proteins 0.000 abstract description 15
241000700605 Viruses Species 0.000 abstract description 11
210000004698 lymphocyte Anatomy 0.000 abstract description 11
108010041397 CD4 Antigens Proteins 0.000 abstract description 8
230000004927 fusion Effects 0.000 abstract description 8
238000000338 in vitro Methods 0.000 abstract description 6
230000034217 membrane fusion Effects 0.000 abstract description 6
108091035707 Consensus sequence Proteins 0.000 abstract description 5
210000002919 epithelial cell Anatomy 0.000 abstract description 5
210000000170 cell membrane Anatomy 0.000 abstract description 4
210000001072 colon Anatomy 0.000 abstract description 4
239000002253 acid Substances 0.000 abstract description 2
150000007513 acids Chemical class 0.000 abstract 1
238000004242 micellar liquid chromatography Methods 0.000 description 61
210000004027 cell Anatomy 0.000 description 58
208000002839 megalencephalic leukoencephalopathy with subcortical cysts Diseases 0.000 description 58
241000713772 Human immunodeficiency virus 1 Species 0.000 description 53
241000283973 Oryctolagus cuniculus Species 0.000 description 36
208000015181 infectious disease Diseases 0.000 description 32
229940024606 amino acid Drugs 0.000 description 20
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 19
235000001014 amino acid Nutrition 0.000 description 19
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 18
241000713340 Human immunodeficiency virus 2 Species 0.000 description 17
230000015572 biosynthetic process Effects 0.000 description 17
102100034349 Integrase Human genes 0.000 description 14
239000000427 antigen Substances 0.000 description 14
102000036639 antigens Human genes 0.000 description 14
108091007433 antigens Proteins 0.000 description 14
102000005962 receptors Human genes 0.000 description 13
230000005764 inhibitory process Effects 0.000 description 12
DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 12
208000037357 HIV infectious disease Diseases 0.000 description 10
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 9
239000000178 monomer Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
230000009257 reactivity Effects 0.000 description 8
231100000331 toxic Toxicity 0.000 description 8
230000002588 toxic effect Effects 0.000 description 8
238000002965 ELISA Methods 0.000 description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
241000699670 Mus sp. Species 0.000 description 6
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 6
230000000903 blocking effect Effects 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000010348 incorporation Methods 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
239000003226 mitogen Substances 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
239000004472 Lysine Substances 0.000 description 5
239000012980 RPMI-1640 medium Substances 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
230000007910 cell fusion Effects 0.000 description 5
239000012894 fetal calf serum Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
208000030507 AIDS Diseases 0.000 description 4
150000008574 D-amino acids Chemical class 0.000 description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
108010047620 Phytohemagglutinins Proteins 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
238000007499 fusion processing Methods 0.000 description 4
229960000310 isoleucine Drugs 0.000 description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000001885 phytohemagglutinin Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
238000005406 washing Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
101100408068 Amanita phalloides PHA1 gene Proteins 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
230000005875 antibody response Effects 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229940000635 beta-alanine Drugs 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
235000019833 protease Nutrition 0.000 description 3
208000015476 pseudohypoaldosteronism type 1 Diseases 0.000 description 3
108010043277 recombinant soluble CD4 Proteins 0.000 description 3
230000004044 response Effects 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
LGGRPYXPOUIMKG-OJICBBQQSA-N (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]pentanediamide Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]([C@@H](C)O)N LGGRPYXPOUIMKG-OJICBBQQSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
101150117151 Cand2 gene Proteins 0.000 description 2
DXENDDMPDZMHSQ-UHFFFAOYSA-N Candinine Chemical compound C12=NC3=CC=CC=C3C(=O)N1C1=CC=CC=C1C2=C1C(=O)C2=CC=CC=C2N1 DXENDDMPDZMHSQ-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
150000008575 L-amino acids Chemical group 0.000 description 2
238000000134 MTT assay Methods 0.000 description 2
231100000002 MTT assay Toxicity 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
-1 acrylic ester Chemical class 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
238000001262 western blot Methods 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
DXENDDMPDZMHSQ-FMQUCBEESA-N Candidine Natural products C12=NC3=CC=CC=C3C(=O)N1C1=CC=CC=C1/C2=C1/C(=O)C2=CC=CC=C2N1 DXENDDMPDZMHSQ-FMQUCBEESA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
108010083930 HIV Receptors Proteins 0.000 description 1
102000006481 HIV Receptors Human genes 0.000 description 1
101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
102100020873 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
241000282553 Macaca Species 0.000 description 1
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
108070000030 Viral receptors Proteins 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003141 anti-fusion Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008275 binding mechanism Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000003570 cell viability assay Methods 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940106189 ceramide Drugs 0.000 description 1
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
238000001514 detection method Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
238000002976 reverse transcriptase assay Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000007501 viral attachment Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

APAP/P/1994/000680A 1993-09-13 1994-09-13 Multiple branch peptide constructions for use against HIV. AP502A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB939318901A GB9318901D0 (en)	1993-09-13	1993-09-13	Multiple branch peptide construction
US08/260,086 US5622933A (en)	1993-09-13	1994-06-15	Multiple branch peptide constructions for use against HIV

Publications (2)

Publication Number	Publication Date
AP9400680A0 AP9400680A0 (en)	1994-10-31
AP502A true AP502A (en)	1996-06-07

Family

ID=26303508

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1994/000680A AP502A (en)	1993-09-13	1994-09-13	Multiple branch peptide constructions for use against HIV.

Country Status (15)

Country	Link
EP (1)	EP0719281B1 (de)
CN (1)	CN1130911A (de)
AP (1)	AP502A (de)
AT (1)	ATE183201T1 (de)
AU (1)	AU7619694A (de)
BR (1)	BR9407530A (de)
DE (1)	DE69420042T2 (de)
DK (1)	DK0719281T3 (de)
ES (1)	ES2137378T3 (de)
GR (1)	GR3031367T3 (de)
HU (1)	HUT75092A (de)
IL (1)	IL110929A0 (de)
OA (1)	OA10271A (de)
PL (1)	PL313520A1 (de)
WO (1)	WO1995007929A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2719049B1 (fr) *	1994-04-22	1996-06-14	Pasteur Institut	Multireprésentation d'un analogue peptidique du substrat de la DPPIV, notamment de type KPR, afin d'inhiber l'entrée du HIV dans les cellules.
GB9627114D0 (en) *	1996-12-31	1997-02-19	Centre Nat Rech Scient	Multiple branch peptide constructions
GB9727424D0 (en) *	1997-12-31	1998-02-25	Armel Sa	Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus
CN1100564C (zh) *	2001-08-29	2003-02-05	周根发	用于治疗hiv感染的药物、其组合物及其用途
AU2004240765B2 (en) *	2003-05-20	2009-03-19	Cellpep Sa	Modified antiviral peptides with increased activity and cell membrane affinity
US7604804B2 (en)	2004-02-09	2009-10-20	University Of Maryland Biotechnology Institute	Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric gp120
JP2010537997A (ja) *	2007-08-27	2010-12-09	マサチューセッツインスティテュートオブテクノロジー	二機能性ポリマーに結合させたインフルエンザウイルス阻害剤
CN102532280A (zh) *	2010-12-08	2012-07-04	吉林大学	一种hiv免疫原及其制备
CN104415739A (zh) *	2013-08-28	2015-03-18	天津市阳权医疗器械有限公司	苯乙烯-二乙烯苯医用树脂的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0328403A2 (de) *	1988-02-12	1989-08-16	United Biomedical Inc.	Synthetische vom HIV-GP120-env-Protein abgeleitete Peptide und ihre Anwendung
WO1992017590A1 (en) *	1991-04-02	1992-10-15	Schweiz. Serum- & Impfinstitut Bern	Therapeutic and preventive vaccines for hiv
WO1993003766A1 (en) *	1991-08-13	1993-03-04	Repligen Corporation	Multiple antigen peptides for use as hiv vaccines

1994
- 1994-09-12 IL IL11092994A patent/IL110929A0/xx unknown
- 1994-09-13 AU AU76196/94A patent/AU7619694A/en not_active Abandoned
- 1994-09-13 ES ES94926312T patent/ES2137378T3/es not_active Expired - Lifetime
- 1994-09-13 AP APAP/P/1994/000680A patent/AP502A/en active
- 1994-09-13 CN CN94193388.1A patent/CN1130911A/zh active Pending
- 1994-09-13 HU HU9600594A patent/HUT75092A/hu unknown
- 1994-09-13 WO PCT/GB1994/001992 patent/WO1995007929A1/en not_active Ceased
- 1994-09-13 BR BR9407530A patent/BR9407530A/pt not_active Application Discontinuation
- 1994-09-13 DK DK94926312T patent/DK0719281T3/da active
- 1994-09-13 EP EP94926312A patent/EP0719281B1/de not_active Expired - Lifetime
- 1994-09-13 DE DE69420042T patent/DE69420042T2/de not_active Expired - Fee Related
- 1994-09-13 AT AT94926312T patent/ATE183201T1/de not_active IP Right Cessation
- 1994-09-13 PL PL94313520A patent/PL313520A1/xx unknown
1996
- 1996-03-13 OA OA60794A patent/OA10271A/en unknown
1999
- 1999-09-29 GR GR990402461T patent/GR3031367T3/el unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0328403A2 (de) *	1988-02-12	1989-08-16	United Biomedical Inc.	Synthetische vom HIV-GP120-env-Protein abgeleitete Peptide und ihre Anwendung
WO1992017590A1 (en) *	1991-04-02	1992-10-15	Schweiz. Serum- & Impfinstitut Bern	Therapeutic and preventive vaccines for hiv
WO1993003766A1 (en) *	1991-08-13	1993-03-04	Repligen Corporation	Multiple antigen peptides for use as hiv vaccines

Also Published As

Publication number	Publication date
AP9400680A0 (en)	1994-10-31
EP0719281A1 (de)	1996-07-03
PL313520A1 (en)	1996-07-08
OA10271A (en)	1997-10-07
BR9407530A (pt)	1997-08-26
EP0719281B1 (de)	1999-08-11
IL110929A0 (en)	1994-11-28
ES2137378T3 (es)	1999-12-16
WO1995007929A1 (en)	1995-03-23
HUT75092A (en)	1997-04-28
AU7619694A (en)	1995-04-03
HU9600594D0 (en)	1996-05-28
CN1130911A (zh)	1996-09-11
DE69420042T2 (de)	2000-04-13
DK0719281T3 (da)	2000-03-20
DE69420042D1 (de)	1999-09-16
ATE183201T1 (de)	1999-08-15
GR3031367T3 (en)	2000-01-31

Publication	Publication Date	Title
US6335017B1 (en)	2002-01-01	Compositions and methods for treating viral infections
JPH06340698A (ja)	1994-12-13	Ｈｉｖ−１のインヒビターとしての合成ポリペプチド
HU214439B (hu)	1998-03-30	Eljárás HIV-fertőzések kezelésére alkalmas monoklonális antitestek és peptidek, valamint ezeket tartalmazó gyógyászati készítmények és vakcinák előállítására
CZ2002402A3 (cs)	2002-09-11	Peptid, jeho použití tripeptidu, způsob určení tripeptidu
EP1466924B9 (de)	2013-06-19	Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper
AP502A (en)	1996-06-07	Multiple branch peptide constructions for use against HIV.
US5622933A (en)	1997-04-22	Multiple branch peptide constructions for use against HIV
US8029797B2 (en)	2011-10-04	Multivalent HIV immunogenic compositions comprising a pool of lipidated and nonlipidated peptides representing Gag and Env variable regions
CA2274853C (en)	2007-05-29	Multiple branch peptide constructions
AU733234B2 (en)	2001-05-10	Conjugated peptides, immunological reagent containing same and use thereof for treatment of immunological disorders
CA2171531C (en)	2005-11-22	Multiple branch peptide constructions for use against hiv
CA2317107C (en)	2008-03-11	Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus
JP3725899B6 (ja)	2006-02-22	Ｈｉｖに対して使用するための多分岐ペプチド構築物
US7285621B2 (en)	2007-10-23	Multiple branch peptide construction
AU2006200455A1 (en)	2006-02-23	Compositions and methods for treating viral infections
HK1072264B (en)	2011-08-26	Synthetic peptide vaccines for hiv: the cbd epitope as an effective immunogen to elicit broadly neutralizing antibodies against hiv
MXPA99003380A (en)	2000-12-06	Compositions and methods for treating viral infections
HK1023371B (en)	2007-12-21	Compositions and methods for treating viral infections
AU2004201321A1 (en)	2004-04-29	Compositions and methods for treating viral infections